44 related articles for article (PubMed ID: 38752436)
1. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
[TBL] [Abstract][Full Text] [Related]
2. Sonogenetics-controlled synthetic designer cells for cancer therapy in tumor mouse models.
Gao T; Niu L; Wu X; Dai D; Zhou Y; Liu M; Wu K; Yu Y; Guan N; Ye H
Cell Rep Med; 2024 May; 5(5):101513. PubMed ID: 38608697
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors stabilize the expression of PD-L1 on cell membrane depending on the phosphorylation of GSK3β.
Gao L; Liu Y; Liu J; Li J; Li H; Liu Y; Meng F; Du X; Gao Y; Li J; Qin FX
Cancer Med; 2024 May; 13(10):e7083. PubMed ID: 38752436
[TBL] [Abstract][Full Text] [Related]
4. Proton Pump Inhibitors and Cancer: Current State of Play.
Bridoux M; Simon N; Turpin A
Front Pharmacol; 2022; 13():798272. PubMed ID: 35359844
[No Abstract] [Full Text] [Related]
5. Gastrointestinal: Pembrolizumab-induced gastric ulcer occurring as an immune-related adverse event.
Terasaki K; Ueno A; Mizuno C; Shima T; Okanoue T
J Gastroenterol Hepatol; 2022 Aug; 37(8):1472. PubMed ID: 35141946
[No Abstract] [Full Text] [Related]
6. Harnessing big data to characterize immune-related adverse events.
Jing Y; Yang J; Johnson DB; Moslehi JJ; Han L
Nat Rev Clin Oncol; 2022 Apr; 19(4):269-280. PubMed ID: 35039679
[TBL] [Abstract][Full Text] [Related]
7. pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition.
Sun Y; Hu L; Yang P; Zhang M; Wang X; Xiao H; Qiao C; Wang J; Luo L; Feng J; Zheng Y; Wang Y; Shi Y; Chen G
Front Immunol; 2021; 12():794226. PubMed ID: 35003115
[TBL] [Abstract][Full Text] [Related]
8. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
Front Immunol; 2021; 12():716317. PubMed ID: 34777340
[TBL] [Abstract][Full Text] [Related]
9. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer.
Qin BD; Jiao XD; Zhou XC; Shi B; Wang J; Liu K; Wu Y; Ling Y; Zang YS
Oncoimmunology; 2021; 10(1):1929727. PubMed ID: 34350061
[TBL] [Abstract][Full Text] [Related]
10. WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.
Wu M; Xia X; Hu J; Fowlkes NW; Li S
Nat Commun; 2021 Jun; 12(1):3500. PubMed ID: 34108491
[TBL] [Abstract][Full Text] [Related]
11. Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.
Cybulska-Stopa B; Ziętek M; Czarnecka AM; Piejko K; Dziura R; Galus Ł; Ziółkowska B; Kieszko S; Kempa-Kamińska N; Calik J; Seredyńska J; Gądek K; Zemełka T; Teterycz P; Kubiatowski T; Suwiński R; Mackiewicz J; Rutkowski P
J Dermatolog Treat; 2022 Jun; 33(4):2168-2174. PubMed ID: 34057374
[TBL] [Abstract][Full Text] [Related]
12. Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma.
Jun T; Ozbek U; Dharmapuri S; Hardy-Abeloos C; Zhu H; Lin JY; Personeni N; Pressiani T; Nishida N; Lee PC; Lee CJ; Hildebrand H; Nimkar N; Paul S; Fessas P; Naeem M; Bettinger D; Khan U; Saeed A; Huang YH; Kudo M; Rimassa L; Marron TU; Pinato DJ; Ang C
Ther Adv Med Oncol; 2021; 13():17588359211010937. PubMed ID: 33995594
[TBL] [Abstract][Full Text] [Related]
13. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy.
Xiong W; Gao Y; Wei W; Zhang J
Trends Cancer; 2021 Sep; 7(9):837-846. PubMed ID: 33903073
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Doroshow DB; Bhalla S; Beasley MB; Sholl LM; Kerr KM; Gnjatic S; Wistuba II; Rimm DL; Tsao MS; Hirsch FR
Nat Rev Clin Oncol; 2021 Jun; 18(6):345-362. PubMed ID: 33580222
[TBL] [Abstract][Full Text] [Related]
15. The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Li C; Xia Z; Li A; Meng J
Ann Transl Med; 2020 Dec; 8(24):1655. PubMed ID: 33490167
[TBL] [Abstract][Full Text] [Related]
16. Regulation of PD-L1 expression in the tumor microenvironment.
Yi M; Niu M; Xu L; Luo S; Wu K
J Hematol Oncol; 2021 Jan; 14(1):10. PubMed ID: 33413496
[TBL] [Abstract][Full Text] [Related]
17. Broad transcriptional response of the human esophageal epithelium to proton pump inhibitors.
Rochman M; Xie YM; Mack L; Caldwell JM; Klingler AM; Osswald GA; Azouz NP; Rothenberg ME
J Allergy Clin Immunol; 2021 May; 147(5):1924-1935. PubMed ID: 33289661
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
Bagchi S; Yuan R; Engleman EG
Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
